Published in Med Sci Monit on August 03, 2014
Promoter methylation of protocadherin8 is an independent prognostic factor for biochemical recurrence of early-stage prostate cancer. Med Sci Monit (2014) 0.89
Aberrant methylation of CDH13 is a potential biomarker for predicting the recurrence and progression of non muscle invasive bladder cancer. Med Sci Monit (2014) 0.88
Aberrant methylation of PCDH8 is a potential prognostic biomarker for patients with clear cell renal cell carcinoma. Med Sci Monit (2014) 0.85
Effect of Cnidium Lactone on Serum Mutant P53 and BCL-2/BAX Expression in Human Prostate Cancer Cells PC-3 Tumor-Bearing BALB/C Nude Mouse Model. Med Sci Monit (2015) 0.83
PCDH10, a novel p53 transcriptional target in regulating cell migration. Cell Cycle (2015) 0.83
Polymorphisms in NFKB1 and NFKBIA Genes Modulate the Risk of Developing Prostate Cancer among Han Chinese. Med Sci Monit (2015) 0.82
Low LKB1 Expression Results in Unfavorable Prognosis in Prostate Cancer Patients. Med Sci Monit (2015) 0.79
Prognostic Value of Protocadherin10 (PCDH10) Methylation in Serum of Prostate Cancer Patients. Med Sci Monit (2016) 0.78
Identification of γ-synuclein as a stage-specific marker in bladder cancer by immunohistochemistry. Med Sci Monit (2014) 0.78
APC methylation predicts biochemical recurrence of patients with prostate cancer: a meta-analysis. Int J Clin Exp Med (2015) 0.77
Epigenetic silencing of protocadherin 10 in colorectal cancer. Oncol Lett (2017) 0.75
NUDT11 rs5945572 polymorphism and prostate cancer risk: a meta-analysis. Int J Clin Exp Med (2015) 0.75
Cancer statistics, 2014. CA Cancer J Clin (2014) 72.81
Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature. Eur Urol (2013) 2.46
Absolute quantitation of DNA methylation of 28 candidate genes in prostate cancer using pyrosequencing. Dis Markers (2011) 1.56
Prostate cancer in Asian men. Nat Rev Urol (2014) 1.46
Global methylation profiling for risk prediction of prostate cancer. Clin Cancer Res (2012) 1.30
DNA methylation signatures for prediction of biochemical recurrence after radical prostatectomy of clinically localized prostate cancer. J Clin Oncol (2013) 1.30
Discovery and validation of 3 novel DNA methylation markers of prostate cancer prognosis. J Urol (2007) 1.08
Epigenetic biomarkers in prostate cancer: Current and future uses. Cancer Lett (2012) 1.07
Predicting the risk of bone metastasis in prostate cancer. Cancer Treat Rev (2013) 1.03
DNA methylation changes in prostate cancer. Methods Mol Biol (2012) 1.00
Aberrant DNA methylation and prostate cancer. Curr Genomics (2011) 0.98
Epigenetic alteration: new insights moving from tissue to plasma - the example of PCDH10 promoter methylation in colorectal cancer. Br J Cancer (2013) 0.94
Clinical and prognostic significance of protocadherin-10 (PCDH10) promoter methylation in bladder cancer. J Int Med Res (2012) 0.94
Circulating free testosterone is an independent predictor of advanced disease in patients with clinically localized prostate cancer. World J Urol (2012) 0.94
Whole-genome methylation sequencing reveals distinct impact of differential methylations on gene transcription in prostate cancer. Am J Pathol (2013) 0.93
Nucleic acid-based tissue biomarkers of urologic malignancies. Crit Rev Clin Lab Sci (2014) 0.93
Methylation markers for prostate cancer prognosis: a systematic review. Cancer Causes Control (2013) 0.92
Combined overexpression of HIVEP3 and SOX9 predicts unfavorable biochemical recurrence-free survival in patients with prostate cancer. Onco Targets Ther (2014) 0.92
PSA mass as a marker of prostate cancer progression after radical prostatectomy. Med Sci Monit (2011) 0.90
Protocadherin 10 is frequently downregulated by promoter methylation and functions as a tumor suppressor gene in non-small cell lung cancer. Cancer Biomark (2013) 0.89
Evidence of perineural invasion on prostate biopsy specimen and survival after radical prostatectomy. Urology (2013) 0.89
Bicalutamide-induced hepatotoxicity: A rare adverse effect. Am J Case Rep (2014) 0.88
Emerging biomarkers for prostate cancer diagnosis, staging, and prognosis. Arch Esp Urol (2011) 0.86
Epigenetic inactivation of PCDH10 in human prostate cancer cell lines. Cell Biol Int (2011) 0.86
PCDH10 promoter hypermethylation is frequent in most histologic subtypes of mature lymphoid malignancies and occurs early in lymphomagenesis. Genes Chromosomes Cancer (2013) 0.84
Seasonality pattern of breast, colorectal, and prostate cancer is dependent on latitude. Med Sci Monit (2014) 0.84
Downregulation of protocadherin-10 expression correlates with malignant behaviour and poor prognosis in human bladder cancer. J Int Med Res (2013) 0.80
The clinical significance of PCDH10 promoter methylation in patients with bladder transitional cell carcinoma. Urol Int (2012) 0.80
Is there any clinical parameter able to predict prostate cancer after initial diagnosis of atypical small acinar proliferation? Urol Int (2008) 0.80
Effectiveness of epidural versus alternate analgesia for pain relief after radical prostatectomy and correlation with biochemical recurrence in men with prostate cancer. Res Rep Urol (2013) 0.79